Previous 10 | Next 10 |
2024-03-27 08:15:03 ET Canaccord Genuity analyst issues BUY recommendation for RANI on March 27, 2024 06:44AM ET. The previous analyst recommendation was Buy. RANI was trading at $3.18 at issue of the analyst recommendation. Historical Analyst Recommendations Lates...
2024-03-20 19:05:06 ET Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Conference Call March 20, 2024, 04:30 PM ET Company Participants Kiki Patel - Gilmartin Group LLC Talat Imran - Chief Executive Officer Arvinder Dhalla - Vice President, Clinical ...
2024-03-20 16:17:53 ET More on Rani Therapeutics Seeking Alpha’s Quant Rating on Rani Therapeutics Historical earnings data for Rani Therapeutics Financial information for Rani Therapeutics Read the full article on Seeking Alpha For further det...
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and web...
Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release ...
2024-02-05 08:31:42 ET Chenghe Acquisition ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...
2024-02-05 08:25:25 ET More on pre-market losers & stocks. Livent: Undervalued With Significant Upside Potential Livent: Wonderful Company Fairly Valued Livent And Albemarle: 2 Lithium Stocks To Buy Now Livent and Allkem shareholders approve merger of equ...
- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial that meets its primary endpoints – ...
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data support the potential for the RaniPill platform to enable oral delivery of multiple obesity treatments - SAN JOSE, Calif., Dec. 14, ...
News, Short Squeeze, Breakout and More Instantly...
Rani Therapeutics Holdings Inc. Company Name:
RANI Stock Symbol:
NASDAQ Market:
2024-05-16 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-st...
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will parti...